Since the level of soluble PD-L1 is increased in the serum of cancer patients and correlates with poor prognosis [15, 16], and sPD-L1 is able to interfere with the activation of blood T cells [17–19], the functional elimination of sPD-L1 could provide a positive therapeutic role by increasing the immune competence of T cells circulating in the blood. The gene discussed is SPDL1; the disease is cancer.